The FDA Removed Black Box Warnings from Some Hormone Therapies — A Functional Medicine Perspective on What This Really Means

Having removed most of the longstanding black box warnings on hormone therapies does not remove the need for safety considerations around them.

About three months ago, the U.S. Food and Drug Administration (FDA) announced it would remove the long-standing black box warning from most hormone replacement therapy (HRT) medications used during menopause. The announcement was widely celebrated, with many interpreting it as confirmation that hormone therapy is broadly safe and long misunderstood.

From a functional medicine perspective, however, this change deserves a more careful, contextual interpretation.

Yes, the science has evolved. But biology is complex, risk is individualized, and labeling changes do not replace thoughtful clinical judgment. For patients — especially those with a personal or family history of breast cancer — this decision raises important questions about how evidence is interpreted, how risk is framed, and how treatment decisions should truly be made.

Understanding the Black Box Warning — and Why It Mattered

A black box warning is the FDA’s strongest safety alert. It signals that a medication carries potentially serious risks and should be prescribed with caution.

For over 20 years, all estrogen-containing menopause hormone therapies (also called menopause hormone therapy, or MHT) carried this warning. This was largely based on data from the Women’s Health Initiative, which showed increased risks of breast cancer, cardiovascular disease, blood clots, and stroke in certain populations using systemic hormone therapy.

While those findings were never meant to suggest that all hormone therapy was dangerous for all people, the warning became a blunt instrument — discouraging individualized care and often leaving symptomatic patients without meaningful support.

Why the FDA Changed Course

The FDA’s recent decision was driven primarily by evidence showing that vaginal estrogen, a low-dose, localized therapy used for vaginal dryness and genitourinary symptoms of menopause, does not significantly raise estrogen levels in the bloodstream.

From a functional medicine standpoint, this distinction matters. Route of administration, dose, tissue exposure, and downstream metabolic effects are not interchangeable — and never were.

Major medical organizations supported removing the black box warning for vaginal estrogen products, citing decades of reassuring safety data, including use in many breast cancer survivors.

However, the FDA also modified labeling language for systemic HRT (pills, patches, injections), and this is where concerns emerge.

Concerns About the Decision-Making Process

In functional medicine, we value diverse perspectives, biological humility, and transparency — especially when dealing with complex, hormone-sensitive conditions.

Critics of the FDA decision have pointed out that the panel involved in revising HRT labeling was largely composed of experts who had already publicly challenged the original black box warning and supported broader hormone therapy use. This raised concerns that the panel may have entered the process with a foregone conclusion, rather than representing the full spectrum of scientific and clinical viewpoints.

Notably underrepresented were clinicians who routinely manage hormone-sensitive cancers and long-term metabolic consequences of hormone exposure.

For patients, this doesn’t mean the data supporting safer use of certain therapies is wrong — but it does mean the decision reflects one interpretive lens, not a universal declaration of safety.

Why Simplified Messaging Misses the Mark

Functional medicine recognizes that health rarely fits into binary categories of “safe” or “unsafe.”

Public messaging around hormone therapy has swung dramatically over the years — from fear-based avoidance to benefit-heavy reassurance. Neither extreme reflects biological reality.

Hormone therapy is a systems-level intervention. It influences inflammation, immune signaling, breast tissue, cardiovascular function, insulin sensitivity, liver metabolism, and detoxification pathways — all of which vary widely between individuals.

HRT Is Not One-Size-Fits-All — Biologically or Clinically

From a functional medicine perspective, the question is not “Is HRT safe?” but rather:

Safe for whom, in what form, at what dose, at what time, and in what biological context?

Key factors include:

• Severity and type of menopausal symptoms

• Age and proximity to menopause

• Personal and family history of breast cancer

• Hormone receptor status of any prior cancer

• Inflammatory burden, metabolic health, and liver function

• Environmental estrogen exposure and detoxification capacity

For some patients, hormone therapy can be profoundly supportive. For others, it may introduce unnecessary risk.

Vaginal Estrogen vs. Systemic HRT: A Functional Distinction

Functional medicine emphasizes delivery matters.

Vaginal estrogen

• Low-dose and localized

• Minimal systemic absorption

• Primarily affects local tissues

• Generally considered low risk for many patients, including some breast cancer survivors

Systemic HRT

• Raises circulating hormone levels

• Affects multiple organ systems

• Combination estrogen-progesterone therapy used long-term may slightly increase breast cancer risk in people without prior cancer

• May increase breast density and complicate screening

• Requires careful consideration in those with hormone-sensitive cancer risk

These therapies should not be discussed — or prescribed — as equivalent.

Breast Cancer History Requires Extra Nuance

Historically, systemic HRT was avoided in breast cancer survivors due to recurrence risk. While newer data suggest this risk is not uniform, functional medicine clinicians emphasize that risk assessment must go beyond population averages.

Tumor biology, estrogen metabolism, inflammatory signaling, and immune surveillance all matter.

For some individuals with severe symptoms, carefully selected hormone therapy may be considered. For others, especially those with hormone-receptor positive disease, caution remains warranted — regardless of label changes.

Timing, Dose, and Duration Are Foundational

Even proponents of hormone therapy agree:

• Earlier initiation (within 10 years of menopause) carries lower risk

• Starting after age 60 increases adverse outcomes

• Lowest effective dose is preferred

• Shortest necessary duration reduces cumulative exposure

Functional medicine further considers how hormones are metabolized, not just how much is prescribed.

Estrogen-Only Therapy Still Carries a Warning

The FDA continues to require a black box warning for estrogen-only HRT due to increased risk of uterine and endometrial cancer. This therapy is typically reserved for people without a uterus.

While estrogen-only therapy has not been linked to increased breast cancer risk in those without prior cancer, it still requires thoughtful risk assessment.

Non-Hormonal and Root-Cause Options Matter

Functional medicine places strong emphasis on non-hormonal strategies, including:

• Addressing inflammation and metabolic health

• Supporting sleep, stress response, and nervous system regulation

• Nutritional and botanical approaches

• New FDA-approved non-hormonal medications for hot flashes

For many patients, these approaches can meaningfully reduce symptoms without altering systemic hormone levels.

What This FDA Change Really Means — Through a Functional Medicine Lens

The FDA’s decision three months ago does not mean hormone therapy is universally safe — nor does it negate decades of valid concern.

What it does mean is:

• The science is more nuanced than it once was

• Some therapies are safer than previously believed

• Individual biology matters more than labels

In functional medicine, we don’t practice by headlines or warnings alone. We practice by context, pattern recognition, and personalized risk-benefit analysis.

If you’re considering hormone therapy, the most important step isn’t reacting to a label change — it’s engaging in a thoughtful conversation with a clinician who understands menopause, cancer risk, and your unique physiology.

Menopause care isn’t about fear.

But it also isn’t about shortcuts.

References:

1. U.S. Food and Drug Administration. (2025, November 10). HHS Advances Women’s Health, Removes Misleading FDA Warnings on Hormone Replacement Therapy [Press Release]. https://www.fda.gov/news-events/press-announcements/hhs-advances-womens-health-removes-misleading-fda-warnings-hormone-replacement-therapy

2. Makary MA, Nguyen CP, Høeg TB, Tidmarsh GF. Updated Labeling for Menopausal Hormone Therapy. JAMA. 2026;335(2):117–118. doi:10.1001/jama.2025.22259.

3. Wittes J, Braunwald E, Chesney MA, et al. Menopausal Hormone Labels Should Rely on Evidence, Not Opinion. JAMA. Published online February 06, 2026. doi:10.1001/jama.2026.1308

The content and any recommendations in this article are for informational purposes only. They are not intended to replace the advice of the reader's own licensed healthcare professional or physician and are not intended to be taken as direct diagnostic or treatment directives. Any treatments described in this article may have known and unknown side effects and/or health hazards. Each reader is solely responsible for his or her own healthcare choices and decisions. The author advises the reader to discuss these ideas with a licensed naturopathic physician.